Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma.

[1]  L. Mariani,et al.  Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). , 2022, JAMA oncology.

[2]  Wei He,et al.  Prognostic Factors and a Nomogram Predicting Overall Survival and Cancer-Specific Survival for Patients with Collecting Duct Renal Cell Carcinoma , 2021, BioMed research international.

[3]  Wenquan Zhou,et al.  Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study , 2021, Frontiers in Oncology.

[4]  F. Saad,et al.  Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. , 2020, European urology focus.

[5]  F. Saad,et al.  Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis , 2020, World Journal of Urology.

[6]  H. Miyake,et al.  Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney , 2019, International Cancer Conference Journal.

[7]  M. Colecchia,et al.  Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. , 2019, Cancer treatment reviews.

[8]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[9]  Y. Nagashima,et al.  Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy , 2018, Medicine.

[10]  F. Zhou,et al.  Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.

[11]  A. Briganti,et al.  Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.

[12]  A. Roychoudhury,et al.  Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. , 2017, Urologic oncology.

[13]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[14]  J. Hainsworth,et al.  Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. , 2016, The Lancet. Oncology.

[15]  Y. Allory,et al.  Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  T. Polascik,et al.  Characteristics and outcomes of tumors arising from the distal nephron. , 2012, Urology.

[17]  H. Miyake,et al.  Metastatic collecting duct carcinoma of the kidney responded to sunitinib , 2010, International Journal of Clinical Oncology.

[18]  J. Wright,et al.  Effect of collecting duct histology on renal cell cancer outcome. , 2009, The Journal of urology.

[19]  S. Culine,et al.  Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.

[20]  N. Rioux-Leclercq,et al.  Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.

[21]  S. Naito,et al.  Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.